Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.58 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.58 |
| ▸ | HCAR2 | Q8TDS4 | 12/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1906699 | 1.00 | MAPT (0.58) | MAPTCACNA1BAPBA1HCAR2APP | |
| SCHEMBL27834457 | 0.98 | MAPT (0.60) | MAPTCACNA1BAPBA1HCAR2APP | |
| SCHEMBL254252 | 0.98 | MAPT (0.60) | MAPTCACNA1BAPBA1HCAR2APP | |
| Fumaric Acid SCHEMBL27729433 | 0.98 | MAPT (0.60) | MAPTCACNA1BAPBA1HCAR2APP | |
| SCHEMBL39644 | 0.98 | MAPT (0.60) | MAPTCACNA1BAPBA1HCAR2APP | |
| Fumaric Acid SCHEMBL27834458 | 0.98 | MAPT (0.60) | MAPTCACNA1BAPBA1HCAR2APP | |
| SCHEMBL39643 | 0.98 | MAPT (0.60) | MAPTCACNA1BAPBA1HCAR2APP | |
| SCHEMBL29985915 | 0.98 | MAPT (0.60) | MAPTCACNA1BAPBA1HCAR2APP | |
| Ethylene SCHEMBL436694 | 0.96 | MAPT (0.58) | MAPTCACNA1BAPBA1HCAR2APP | |
| SCHEMBL1906274 | 0.96 | MAPT (0.58) | MAPTCACNA1BAPBA1HCAR2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080233185-A1 | Fumaric Acid Derivatives as NF-kappaB Inhibitor | FUMAPHARM AG | 2008-09-25 | — | — | US | claimed |
| EP-1248606-B1 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES | FUMAPHARM AG (CH) | 2006-06-14 | — | — | EP | claimed |
| US-6858750-B2 | Use of fumaric acid derivatives for treating mitochondrial diseases | FUMAPHARM AG (CH) | 2005-02-22 | — | — | US | claimed |
| US-20040054001-A1 | Fumaric acid derivatives as nf-kappab inhibitors | FUMAPHARM AG (CH) | 2004-03-18 | — | — | US | claimed |
| WO-2016074684-A1 | FUMARIC ACID DERIVATIVES FOR MEDICAL USE | SYDDANSK UNIVERSITET (DK) | 2016-05-19 | — | — | WO | disclosed |
| US-20160030374-A1 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA | FUMAPHARM AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-8980832-B2 | Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma | BIOGEN IDEC INTERNATIONAL GMBH (CH) | 2015-03-17 | — | — | US | disclosed |
| US-20110124615-A1 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA | FUMAPHARM AG | 2011-05-26 | — | — | US | disclosed |
| US-20080233185-A1 | Fumaric Acid Derivatives as NF-kappaB Inhibitor | FUMAPHARM AG | 2008-09-25 | — | — | US | disclosed |
| EP-1913942-A2 | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma | Fumapharm AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| EP-1663197-B1 | THE USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA | FUMAPHARM AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| US-20070027076-A1 | Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma | FUMAPHAM AG | 2007-02-01 | — | — | US | disclosed |
| EP-1663197-A1 | THE USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA | Fumapharm AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023241-A1 | THE USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA | FUMAPHARM AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| US-6858750-B2 | Use of fumaric acid derivatives for treating mitochondrial diseases | FUMAPHARM AG (CH) | 2005-02-22 | — | — | US | disclosed |
| US-20040054001-A1 | Fumaric acid derivatives as nf-kappab inhibitors | FUMAPHARM AG (CH) | 2004-03-18 | — | — | US | disclosed |
| US-20030013761-A1 | Use of fumaric acid derivatives for treating mitochondrial diseases | BIOGEN INTERNATIONAL GMBH (CH) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054001-A1 | Fumaric acid derivatives as nf-kappab inhibitors | NFKBIA, NFKB1, NFKB2 | MAPT 730/4885CACNA1B 4032/4885APBA1 251/4885 |
| US-20160030374-A1 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA | FH, FAH, AADAC | MAPT 4232/4885CACNA1B 595/4885APBA1 2089/4885 |
| US-20080233185-A1 | Fumaric Acid Derivatives as NF-kappaB Inhibitor | NFKBIA, NFKB1, NFKB2 | MAPT 743/4885CACNA1B 4011/4885APBA1 254/4885 |
| US-20070027076-A1 | Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma | FH, FAH, AADAC | MAPT 4232/4885CACNA1B 595/4885APBA1 2089/4885 |
| US-20030013761-A1 | Use of fumaric acid derivatives for treating mitochondrial diseases | FH, HADHA, HADH | MAPT 139/4885CACNA1B 4332/4885APBA1 1241/4885 |
| US-20110124615-A1 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA | FH, FAH, AADAC | MAPT 4232/4885CACNA1B 595/4885APBA1 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.